These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16904114)

  • 61. At last, an orally active gonadotropin-releasing hormone antagonist.
    Paulson RJ
    Fertil Steril; 2019 Jan; 111(1):30-31. PubMed ID: 30611410
    [No Abstract]   [Full Text] [Related]  

  • 62. Hormone dependence and hormone production of isografted granulosa-cell tumours in mice.
    VAN NIE R
    Acta Physiol Pharmacol Neerl; 1957 Oct; 5(4):495-6. PubMed ID: 13487348
    [No Abstract]   [Full Text] [Related]  

  • 63. Corrigendum: Bisphenol-A exposure and gene expression in human luteinized membrana granulosa cells in vitro.
    Mansur A; Israel A; Combelles CMH; Adir M; Racowsky C; Hauser R; Baccarelli AA; Machtinger R
    Hum Reprod; 2018 May; 33(5):989. PubMed ID: 29608675
    [No Abstract]   [Full Text] [Related]  

  • 64. Effect of Hyperin and Icariin on steroid hormone secretion in rat ovarian granulosa cells （Erratum）.
    Nie X; Sheng W; Hou D; Liu Q; Wang R; Tan Y
    Clin Chim Acta; 2024 Jan; 552():117681. PubMed ID: 38040048
    [No Abstract]   [Full Text] [Related]  

  • 65. Corrigendum to "Effect of Hyperin and Icariin on steroid hormone secretion in rat ovarian granulosa cells" [J. Clin. Chim. Acta 495 (2019) 646-651].
    Nie X; Sheng W; Hou D; Liu Q; Wang R; Tan Y
    Clin Chim Acta; 2023 Nov; 551():117649. PubMed ID: 37977716
    [No Abstract]   [Full Text] [Related]  

  • 66. The HERA (Hyper-response Risk Assessment) Delphi consensus for the management of hyper-responders in in vitro fertilization.
    Feferkorn I; Santos-Ribeiro S; Ubaldi FM; Velasco JG; Ata B; Blockeel C; Conforti A; Esteves SC; Fatemi HM; Gianaroli L; Grynberg M; Humaidan P; Lainas GT; La Marca A; Craig LB; Lathi R; Norman RJ; Orvieto R; Paulson R; Pellicer A; Polyzos NP; Roque M; Sunkara SK; Tan SL; Urman B; Venetis C; Weissman A; Yarali H; Dahan MH
    J Assist Reprod Genet; 2023 Nov; 40(11):2681-2695. PubMed ID: 37713144
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A Second Dose of GnRHa in Combination with Luteal GnRH Antagonist May Eliminate Ovarian Hyperstimulation Syndrome in Women with ≥30 Follicles Measuring ≥11 mm in Diameter on Trigger Day and/or Pre-trigger Peak Estradiol Exceeding 10 000 pg/mL.
    Deng L; Li XL; Ye DS; Blockeel C; Zhou XY; Chen SL; Chen X
    Curr Med Sci; 2019 Apr; 39(2):278-284. PubMed ID: 31016522
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series.
    Lee D; Kim SJ; Hong YH; Kim SK; Jee BC
    Obstet Gynecol Sci; 2017 Sep; 60(5):449-454. PubMed ID: 28989921
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome.
    Chappell N; Gibbons WE
    Clin Exp Reprod Med; 2017 Jun; 44(2):57-62. PubMed ID: 28795043
    [TBL] [Abstract][Full Text] [Related]  

  • 70. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 71. GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
    Fouda UM; Sayed AM; Elshaer HS; Hammad BE; Shaban MM; Elsetohy KA; Youssef MA
    J Ovarian Res; 2016 May; 9(1):29. PubMed ID: 27184139
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cetrotide administration in the early luteal phase in patients at high risk of ovarian hyperstimulation syndrome: A controlled clinical study.
    Wang YQ; Yu N; Xu WM; Xie QZ; Yan WJ; Wu GX; Yang J
    Exp Ther Med; 2014 Dec; 8(6):1855-1860. PubMed ID: 25371744
    [TBL] [Abstract][Full Text] [Related]  

  • 73. VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status.
    Naredi N; Talwar P; Sandeep K
    Med J Armed Forces India; 2014 Jan; 70(1):58-63. PubMed ID: 24623949
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Tarlatzi TB; Tarlatzis BC; Lainas TG
    Reprod Biol Endocrinol; 2012 Aug; 10():69. PubMed ID: 22938051
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro.
    Shah DK; Menon KM; Cabrera LM; Vahratian A; Kavoussi SK; Lebovic DI
    Fertil Steril; 2010 Apr; 93(6):2042-7. PubMed ID: 19342033
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures.
    Asimakopoulos B; Nikolettos N; Nehls B; Diedrich K; Al-Hasani S; Metzen E
    Fertil Steril; 2006 Sep; 86(3):636-41. PubMed ID: 16904114
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effects of cetrorelix and triptorelin on the viability and steroidogenesis of cultured human granulosa luteinized cells.
    Metallinou C; Köster F; Diedrich K; Nikolettos N; Asimakopoulos B
    In Vivo; 2012; 26(5):835-9. PubMed ID: 22949598
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Adrenomedullin and vascular endothelial growth factor production by follicular fluid macrophages and granulosa cells.
    Balasch J; Guimerá M; Martinez-Pasarell O; Ros J; Vanrell JA; Jiménez W
    Hum Reprod; 2004 Apr; 19(4):808-14. PubMed ID: 15016771
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Levels of apoptosis in human granulosa cells seem to be comparable after therapy with a gonadotropin-releasing hormone agonist or antagonist.
    Giampietro F; Sancilio S; Tiboni GM; Rana RA; Di Pietro R
    Fertil Steril; 2006 Feb; 85(2):412-9. PubMed ID: 16595220
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Clinical application of GnRH antagonist to uterine fibroid].
    Ayabe T
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():116-21. PubMed ID: 16689295
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.